Ranbaxy Halts Atorvastatin Production; Too Late for Mylan to Say “I Told You So?”
This article was originally published in RPM Report
Executive Summary
One year after the biggest generic drug launch in history, Ranbaxy is halting production of atorvastatin after a manufacturing quality glitch. FDA should be grateful this didn’t happen in the first six months – but may also want to start preparing for possible investigations if the new Energy & Commerce/Oversight chairman decides to press a point.